A chromosome analysis test, commonly called a karyotype, examines the number and large-scale structure of chromosomes in dividing cells. It can identify an extra or missing chromosome, a large deletion or duplication, and rearrangements such as translocations or inversions. Doctors may order it to investigate congenital differences, developmental concerns, infertility, repeated pregnancy loss, an abnormal prenatal screen, or certain blood cancers. A typical constitutional result contains 46 chromosomes, but a “normal karyotype” does not rule out most single-gene disorders or small DNA changes because those are below the microscope’s resolution. Results may also show mosaicism, meaning the chromosome finding appears in some tested cells but not others, or a balanced rearrangement that causes no obvious health problem in the carrier yet affects reproductive risk. The sample, number of cells examined, reason for testing, and need for follow-up microarray, FISH, or sequencing all shape what the report means.
- A karyotype counts and visually inspects chromosomes: It detects whole-chromosome changes and many large structural rearrangements.
- The usual constitutional chromosome count is 46: Reports often begin with 46,XX or 46,XY, followed by any identified abnormality.
- A normal result has important limits: Small deletions, duplications, and most gene variants require other testing.
- Turnaround often takes one to three weeks: Cells usually must grow in culture before chromosomes can be examined.
- Balanced does not always mean irrelevant: A balanced translocation may not affect the carrier but can increase miscarriage or abnormal-pregnancy risk.
- Mosaic results depend on the tissue tested: A blood karyotype may not detect a chromosome change confined to another tissue.
Table of Contents
- What a Karyotype Examines
- Why Chromosome Analysis Is Ordered
- How the Laboratory Performs the Test
- Abnormalities a Karyotype Can Detect
- How Karyotype Results Are Written
- Meaning of Normal, Abnormal, and Mosaic Results
- Karyotype Versus Microarray, FISH, and Sequencing
- Follow-Up After Chromosome Results
What a Karyotype Examines
Chromosomes are long DNA molecules packaged with proteins inside the cell nucleus. Most human body cells contain 46 chromosomes arranged in 23 pairs: 22 pairs of autosomes and one pair of sex chromosomes. One chromosome in each pair usually comes from the egg and the other from the sperm.
A karyotype is an organized image and written description of these chromosomes. Laboratory specialists stop dividing cells at a stage when the chromosomes are condensed and visible, stain them to create a banding pattern, photograph them under a microscope, and arrange them by size and characteristic features.
The test evaluates three broad properties:
- Number: whether a chromosome is present in the expected number
- Structure: whether large chromosome segments are missing, duplicated, reversed, exchanged, or attached elsewhere
- Cell-to-cell consistency: whether all examined cells show the same chromosome pattern
A constitutional karyotype assesses chromosome changes present from conception or early development. It may use blood, amniotic fluid, chorionic villi, skin, products of conception, or another tissue. An acquired karyotype examines changes that developed in a population of cells during life, especially bone marrow or blood cells in leukemia and related disorders.
These two uses should not be confused. A chromosome abnormality found only in cancer cells is not automatically inherited. Conversely, a constitutional rearrangement may appear in many tissues and have implications for biological relatives and future pregnancies.
Karyotyping is a form of chromosome analysis, but the terms are sometimes used more broadly. Some laboratories may use “chromosome study” to include FISH, microarray, or other cytogenomic methods. The order and report should state exactly which method was performed.
Why Chromosome Analysis Is Ordered
A clinician chooses karyotyping when the suspected problem could involve chromosome number or a rearrangement large enough to see under a microscope.
Postnatal diagnosis
A blood karyotype may be ordered for a child or adult with findings that suggest a chromosome syndrome. These may include a distinctive pattern of congenital anomalies, differences in growth or sexual development, primary ovarian insufficiency, ambiguous genital development, or features associated with Down, Turner, or Klinefelter syndrome.
Chromosomal microarray is often a more sensitive first test for unexplained developmental delay, intellectual disability, autism with congenital anomalies, or multiple birth differences because it detects smaller copy-number changes. Karyotyping remains valuable when a whole-chromosome condition, a balanced rearrangement, or certain forms of mosaicism are suspected.
Prenatal diagnosis
Prenatal chromosome analysis may follow a positive cell-free DNA screen, an abnormal ultrasound, a family rearrangement, or a parent’s request for diagnostic information. Cells are obtained through chorionic villus sampling or amniocentesis.
Screening and diagnosis are different. Noninvasive prenatal testing estimates the chance of selected chromosome conditions using placental DNA fragments in maternal blood. A karyotype performed on an invasive sample can directly examine fetal or placental cells and may confirm or clarify the finding.
Infertility and recurrent pregnancy loss
A parental karyotype can identify balanced translocations, inversions, sex-chromosome differences, or mosaicism that may affect sperm production, ovarian function, embryo development, or miscarriage risk.
Most miscarriages caused by chromosome errors arise by chance and do not mean a parent has a rearrangement. Testing is considered when losses are recurrent, fetal or pregnancy-tissue results suggest a structural rearrangement, or reproductive history raises a specific concern.
A products of conception genetic test may use microarray rather than karyotype because microarray does not require living dividing cells and has a lower culture-failure rate. However, microarray cannot identify every balanced rearrangement.
Blood and bone marrow disorders
Cancer cytogenetics looks for acquired chromosome clones in leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms, and some solid tumors. Findings can support diagnosis, prognosis, treatment choice, and disease monitoring.
Cancer reports use specialized rules for determining whether an abnormal cell line is clonal. Interpretation belongs with the hematopathology or oncology assessment and should not be applied directly to inherited reproductive risk.
How the Laboratory Performs the Test
The specimen must contain living cells capable of dividing, unless the laboratory uses an alternative preparation for a particular tissue. This biological requirement explains why karyotyping takes longer and fails more often than tests that analyze extracted DNA directly.
Common sample types
- Peripheral blood: white blood cells are cultured for postnatal constitutional studies.
- Bone marrow: dividing marrow cells are evaluated for acquired cancer-related changes.
- Amniotic fluid: fetal cells are cultured after amniocentesis.
- Chorionic villi: placental tissue is studied after CVS, sometimes with both direct and cultured preparations.
- Products of conception: pregnancy tissue may be cultured, though maternal-cell contamination and culture failure can complicate results.
- Skin biopsy: fibroblasts can be tested when blood is normal but tissue-limited mosaicism is suspected.
- Tumor tissue: selected solid tumors can undergo chromosome analysis when viable cells are available.
The laboratory grows cells under controlled conditions and arrests them in metaphase, when chromosomes are compact. After treatment, fixation, and staining, each chromosome displays alternating light and dark bands. G-banding is the most common constitutional technique.
A cytogenetic technologist counts chromosomes and examines band patterns across multiple cells. The number of cells analyzed depends on the indication, laboratory protocol, specimen quality, and whether mosaicism is suspected. More cells may be counted when the goal is to detect a low-level abnormal cell population.
Resolution is often described by the number of visible bands in a haploid set. A higher band level generally permits smaller structural changes to be recognized, but it still cannot approach the resolution of microarray or DNA sequencing. Typical constitutional studies detect changes measured in millions of DNA base pairs, with performance varying by region and sample quality.
Turnaround commonly ranges from about one to three weeks. Prenatal and urgent cancer testing may receive faster processing. Delays can occur when cells grow slowly, the sample is small, cultures become contaminated, or additional analysis is required.
Possible non-result outcomes include:
- Insufficient sample
- No cell growth
- Poor chromosome quality
- Maternal-cell contamination
- Too few cells for the requested mosaicism assessment
- An ambiguous finding that needs FISH, microarray, or parental testing
A failed culture does not mean the chromosomes are normal or abnormal. It means the laboratory could not produce an interpretable result from that specimen.
Abnormalities a Karyotype Can Detect
A karyotype is strongest at detecting large-scale chromosome changes and rearrangements that preserve the total amount of DNA.
Numerical abnormalities
Aneuploidy means an extra or missing individual chromosome. Examples include:
- Trisomy 21 in Down syndrome
- Trisomy 18 in Edwards syndrome
- Trisomy 13 in Patau syndrome
- Monosomy X in Turner syndrome
- 47,XXY in Klinefelter syndrome
- 47,XYY and 47,XXX chromosome complements
Polyploidy means an extra complete set of chromosomes, such as triploidy with 69 chromosomes. Full triploidy is usually not compatible with long-term survival, though it may be identified in prenatal or pregnancy-loss samples.
Structural abnormalities
A deletion is a missing chromosome segment. A duplication is an extra copy of a segment. Karyotyping can detect sufficiently large deletions and duplications, but smaller changes may require a chromosomal microarray test.
A translocation occurs when chromosome material moves between chromosomes. In a reciprocal translocation, segments are exchanged. In a Robertsonian translocation, long arms of certain acrocentric chromosomes join.
A translocation may be balanced, with no obvious net gain or loss of visible material, or unbalanced, with missing or extra chromosome segments. Balanced carriers may be healthy but can produce eggs or sperm with an unbalanced chromosome complement.
An inversion occurs when a chromosome segment breaks, flips, and reinserts. Many inversions are harmless variants, while others disrupt a gene or create reproductive risk depending on size and location.
Other visible findings include ring chromosomes, marker chromosomes, insertions, isochromosomes, dicentric chromosomes, and complex rearrangements. Follow-up tests may be needed to identify the origin and gene content of a small marker or apparently balanced event.
Mosaicism
Mosaicism means two or more genetically different cell lines developed from one fertilized egg. A report might show a normal line and a line with an extra or missing chromosome.
The percentage observed in the sample is not necessarily the percentage throughout the body. Different tissues can contain different proportions. Culture conditions may also favor one cell line. Clinical effects depend on the chromosome change, tissue distribution, timing in development, and level of mosaicism.
How Karyotype Results Are Written
Karyotype reports use the International System for Human Cytogenomic Nomenclature, or ISCN. The notation compresses the chromosome count, sex-chromosome complement, structural finding, band locations, and sometimes the number of cells into one line.
Common examples include:
| Example | Plain-language meaning |
|---|---|
| 46,XX | 46 chromosomes with two X chromosomes; no visible abnormality reported |
| 46,XY | 46 chromosomes with one X and one Y chromosome; no visible abnormality reported |
| 47,XX,+21 | 47 chromosomes, two X chromosomes, and an extra chromosome 21 |
| 45,X | 45 chromosomes with one X chromosome |
| 47,XXY | 47 chromosomes with two X chromosomes and one Y chromosome |
| 46,XX,t(2;8)(q21;q24) | 46 chromosomes with a translocation between chromosomes 2 and 8 at the listed bands |
| mos 45,X[8]/46,XX[22] | Mosaic result: 8 cells with monosomy X and 22 cells with 46,XX |
The notation alone does not provide the full interpretation. The report should explain whether the finding is constitutional or acquired, balanced or unbalanced, known to cause a syndrome, of uncertain significance, or possibly a normal variant.
Band labels identify chromosome arms and regions. The short arm is “p,” and the long arm is “q.” Numbers move outward from the centromere. A result such as del(5)(p15.2) describes a deletion involving the short arm of chromosome 5 with a breakpoint near band p15.2.
ISCN standards are periodically updated, so the same biological finding may be written with minor nomenclature differences across time. The laboratory’s narrative interpretation and any attached diagram are often more understandable than the string alone.
Meaning of Normal, Abnormal, and Mosaic Results
Normal karyotype
A normal constitutional result means the laboratory did not see a chromosome-number change or structural abnormality at the test’s resolution in the cells examined. It does not prove that the person has no genetic disorder.
A normal karyotype can occur when the cause is:
- A single-gene variant
- A small deletion or duplication
- A repeat expansion
- A methylation or imprinting abnormality
- A mitochondrial DNA variant
- Low-level mosaicism below detection
- Mosaicism confined to another tissue
- A non-genetic condition
The reason for testing determines whether another method is appropriate.
Abnormal unbalanced result
An unbalanced result shows extra or missing chromosome material. The clinical effect depends on the chromosomes and genes involved, the size of the imbalance, mosaicism, and whether it is present in all tissues.
Some findings correspond to well-characterized syndromes. Others are unique or rare and require database review, parental testing, microarray mapping, or specialist evaluation.
Balanced rearrangement
A balanced translocation or inversion may not change the amount of visible chromosome material. Many carriers have no related symptoms. However, a breakpoint can occasionally disrupt a gene, and “apparently balanced” rearrangements may hide small copy-number changes below karyotype resolution.
For reproductive counseling, the shape and chromosomes involved affect the chance of infertility, miscarriage, or a child with an unbalanced rearrangement. A single universal risk percentage is not appropriate.
Mosaic result
A mosaic report indicates that the abnormality was present in only some tested cells. The count in brackets shows how many cells had each pattern. It is a laboratory observation, not a direct measure of symptom severity.
Prenatal mosaicism may reflect the fetus, the placenta only, laboratory culture effects, or a mixture. Additional testing—sometimes amniocentesis after a CVS result, interphase FISH, microarray, or examination of another tissue—may be recommended.
Variant or uncertain chromosome finding
Some heteromorphisms involve differences in repetitive chromosome regions and are considered benign. Other rare rearrangements cannot be fully interpreted by appearance alone. The report may recommend parental studies: an inherited finding in a healthy parent can provide context, although it does not always prove harmlessness.
Karyotype Versus Microarray, FISH, and Sequencing
No single genetic test detects every type of chromosome or DNA change. Karyotyping remains useful because it shows chromosome architecture, but other methods answer different questions.
| Test | Strongest use | Often misses |
|---|---|---|
| Karyotype | Whole-chromosome changes, large rearrangements, balanced translocations | Small copy-number changes and most gene variants |
| FISH | Rapid, targeted look at a known chromosome region or cell population | Changes outside the selected probes |
| Chromosomal microarray | Small genome-wide deletions and duplications | Most balanced rearrangements and some low-level mosaicism |
| Gene panel or exome sequencing | Small variants in disease-associated genes | Many repeat, methylation, and balanced structural changes |
| Genome sequencing | Broad detection of small and some structural variants | Performance varies for repeats, mosaicism, and complex regions |
A FISH test can produce rapid targeted information and can count abnormalities in non-dividing cells. It does not replace a genome-wide karyotype unless the clinical question is limited to the probed region.
Microarray often defines the size and gene content of an imbalance more precisely. Karyotyping can then show whether that imbalance arose from a translocation or another structural mechanism relevant to relatives.
Sequencing is preferable when the suspected condition is caused by variants too small to see cytogenetically. A person can have a normal karyotype and a clearly pathogenic single-gene result.
Follow-Up After Chromosome Results
The follow-up plan should begin with the original clinical question. A result that confirms trisomy 21 requires different care from a balanced parental translocation, an uncertain marker chromosome, or an acquired leukemia clone.
After an abnormal constitutional result, useful steps may include:
- Review the written interpretation with a genetic counselor or medical geneticist.
- Confirm whether the finding is present in all cells tested or is mosaic.
- Determine whether microarray or FISH is needed to define the change.
- Consider parental karyotypes to learn whether the rearrangement was inherited.
- Arrange condition-specific medical evaluations and surveillance.
- Discuss implications for siblings, adult relatives, and future pregnancies.
- Keep the complete report with the exact ISCN notation.
After a normal result, ask what the test could not detect and whether the person’s findings support another method. A normal karyotype should not end an evaluation when clinical evidence remains strong.
For infertility or pregnancy loss, a balanced rearrangement may lead to discussion of natural conception with prenatal diagnosis, IVF with PGT-SR for structural rearrangements, donor gametes, adoption, or no further reproductive testing. The likely outcomes depend on the specific rearrangement and reproductive history.
For prenatal findings, decisions should be based on confirmed diagnostic information, ultrasound findings, mosaicism assessment, and condition-specific counseling. A result from placental tissue may need fetal confirmation when confined placental mosaicism is possible.
For cancer findings, the oncologist or hematologist will integrate the karyotype with morphology, flow cytometry, molecular testing, and treatment response. Relatives generally do not need testing for an acquired cancer clone unless a separate germline concern is identified.
Chromosome results can be emotionally difficult and technically dense. The most useful explanation converts the notation into four clear answers: what changed, whether it is constitutional or acquired, what health or reproductive effects are established, and which test or clinical step comes next.
Before accepting a result as complete, check whether the laboratory answered the intended question. For suspected mosaicism, ask how many cells were counted and whether another tissue could be more informative. For a structural rearrangement, ask whether the report describes it as balanced only by visual inspection and whether microarray is appropriate to look for hidden copy-number changes. For prenatal or miscarriage samples, ask whether maternal-cell contamination was assessed. For cancer studies, ask whether the abnormal clone was present in enough cells to meet laboratory criteria and whether a normal result could reflect limited dividing cells.
Older chromosome reports may use nomenclature that remains biologically valid but is less detailed than current reporting. Repeating the same test is not always necessary; a cytogenetics laboratory may be able to reinterpret the original notation or recommend a more precise modern method. When family testing is planned, provide the complete report rather than only the syndrome name. A relative may need targeted chromosome analysis, a full karyotype, FISH, or microarray depending on what was found.
References
- Karyotype Genetic Test 2025 (Official)
- Genetics, Cytogenetic Testing and Conventional Karyotype 2025 (Review)
- ACGS Best Practice Guidelines for Constitutional Karyotype Analysis and Targeted Chromosome Analysis 2024 (Guideline)
- Genetics, Chromosome Abnormalities 2026 (Review)
- ISCN 2024: Summary of Revisions and New Nomenclature 2025 (Review)
- Prenatal Cell-Free DNA Screening 2024 (Official)
Disclaimer
This article provides general education about chromosome analysis and karyotype results. The meaning of a finding depends on the specimen, indication, cell counts, mosaicism, exact chromosome change, and other clinical data; review an individual report with a qualified genetics, prenatal, hematology, or oncology professional.
